NCT03408132View on ClinicalTrials.gov

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

October 28, 2019

Study Completion Date

October 28, 2019

Conditions
SBS - Short Bowel Syndrome
Interventions
DRUG

FE203799

FE203799 5 mg subcutaneous once weekly

Trial Locations (1)

Unknown

Rigshospitalet, Copenhagen

Sponsors
All Listed Sponsors
collaborator

VectivBio AG

INDUSTRY

lead

GlyPharma Therapeutics

INDUSTRY